Baxter International Inc. (NYSE:BAX) Shares Purchased by TD Private Client Wealth LLC

TD Private Client Wealth LLC grew its stake in Baxter International Inc. (NYSE:BAX - Free Report) by 21.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,438 shares of the medical instruments supplier's stock after purchasing an additional 8,393 shares during the period. TD Private Client Wealth LLC's holdings in Baxter International were worth $1,624,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Dodge & Cox lifted its stake in shares of Baxter International by 13.0% in the 4th quarter. Dodge & Cox now owns 50,377,294 shares of the medical instruments supplier's stock valued at $1,469,002,000 after purchasing an additional 5,779,100 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Baxter International by 40.4% in the fourth quarter. Russell Investments Group Ltd. now owns 1,745,709 shares of the medical instruments supplier's stock worth $50,904,000 after buying an additional 502,370 shares during the period. Sound Shore Management Inc. CT purchased a new stake in shares of Baxter International in the fourth quarter worth approximately $72,450,000. GAMMA Investing LLC raised its holdings in shares of Baxter International by 248.3% in the first quarter. GAMMA Investing LLC now owns 11,326 shares of the medical instruments supplier's stock worth $388,000 after buying an additional 8,074 shares during the period. Finally, Raiffeisen Bank International AG purchased a new stake in shares of Baxter International in the fourth quarter worth approximately $2,193,000. 90.19% of the stock is owned by institutional investors.

Baxter International Stock Down 3.3%

NYSE BAX traded down $0.99 during midday trading on Friday, hitting $28.71. 6,787,866 shares of the company traded hands, compared to its average volume of 4,505,337. The company has a debt-to-equity ratio of 1.33, a current ratio of 2.02 and a quick ratio of 1.40. The company has a market cap of $14.73 billion, a PE ratio of -26.10, a price-to-earnings-growth ratio of 0.88 and a beta of 0.61. The company's 50-day simple moving average is $30.59 and its 200-day simple moving average is $31.24. Baxter International Inc. has a 52 week low of $26.25 and a 52 week high of $40.49.

Baxter International (NYSE:BAX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.14. The business had revenue of $2.63 billion for the quarter, compared to analysts' expectations of $2.59 billion. Baxter International had a positive return on equity of 17.24% and a negative net margin of 4.71%. The business's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.65 EPS. As a group, equities research analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current year.

Baxter International Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, July 1st. Stockholders of record on Friday, May 30th were given a $0.17 dividend. The ex-dividend date was Friday, May 30th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.37%. Baxter International's payout ratio is -61.82%.

Analysts Set New Price Targets

BAX has been the topic of several recent analyst reports. Evercore ISI reduced their price target on Baxter International from $44.00 to $42.00 and set an "outperform" rating on the stock in a report on Tuesday. Wells Fargo & Company reduced their price objective on Baxter International from $36.00 to $33.00 and set an "equal weight" rating on the stock in a report on Friday, May 2nd. Morgan Stanley reduced their price objective on Baxter International from $30.00 to $28.00 and set an "underweight" rating on the stock in a report on Monday, May 5th. Wall Street Zen upgraded Baxter International from a "hold" rating to a "buy" rating in a report on Sunday, June 22nd. Finally, Citigroup reduced their price objective on Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.50.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.